OSTX
OS Therapies Incorporated
Mentions (24Hr)
200.00% Today
Reddit Posts
OS Therapies Chart Looks Crispy: Happy Early Halloween
OS Therapies $OSTX Finally new hope for rare bone cancer? Chart has a decent setup too
OSTX about to shoot up ?
OS Therapies(OSTX) - October 10
$OSTX: Potential for Significant Gains in October Based on Key Biotech Catalysts
OSTX - Huge Upside Potential
$OSTX - BIOTECH MOONSHOT FROM $2 to $20 ππ
Iβm interested in OSTXβ¦? $1.68 with $10-$20 price targets and a lot of hype.
OS Therapies Just Got Their End-of-Phase 2 Meeting with the FDA
Adding a new leg to my biotech pick to click.
My biotech pick is branching out...
Another strategic step towards growth.
Catalyst for my biotech pick!
How did I miss this catalyst!
Biotech's Underdog: $OSTX Making Quiet Moves in Osteosarcoma Treatment
Pivoting back to a long-time biotech favorite.
Pivoting back - a fundamental check-in with a biotech favorite
Biotech Fundamental Check-In: FDA + Public Spotlight Developments
Last TA Update for awhile on my longstanding biotech pick
Post-FDA Reaction TA Update on $OSTX
Post-FDA Reaction to $OSTX - a Technical Update!
Fundamentals catalysts continue for OS Therapies...
More fundamental news catalysts on my long-standing biotech pick.
The streamline of fundamental updates continues in biotech
A round up of small-caps expected to have upside...
My biotech pick from forever is making big-name lists...
Excited to see this catalyst on the biotech pick I've followed for so long!
Biotech Technical Analysis to head into the weekend
Biotech Technical Analysis to head into the weekend
The latest technical breakdown on my longest-standing biotech pick | Good Friday TA
OSTX: Major Trial Results + Strategic Acquisition = A Whole New Chapter
OSTX: Major Trial Results + Strategic Acquisition = A Whole New Chapter
Some of the recent developments on one of my OG biotech picks....
What's been going on with my back-pocket biotech pick?
Haven't checked in on this developing biotech co. in a while...
Mentions
OSTX, SLS, DRTS, CADL if youβre into bioβs. Dont hear CADL get any love at all. Great potential.
Feel like I missed out on everything today, now holding SLS, OSTX and CRDL
OSTX has the news, just needs volume to take off
Waiting for OSTX to pop
OSTX again good news with FDA!
Did anyone else buy into OSTX? The PDUFA waiver and MHRA news were positive. Hopefully, the FDA meeting details will be good and be released soon.
Don't know XPON, OSTX. CGTX and GNS are OK. ATCH is actually good! BURU, VIVK could bounce who knows? Don't know what your entry is on those two if they can bounce enough to get your money back. There are garbage companies though.
Which of my bags are unrecoverable? BURU XPON ATCH CGTX GNS OSTX VIVK
I think OSTX is looking really interesting for the long run. The average predicted price for next year is to good to be true but just 1/4 of it will be amazing.
Oh yes OSTX. Could never forget about this one. Havenβt looked at it in a while. You think the trend line will hold?
OSTX on discount, easy profit play
Watching OSTX. This could be an under-the-radar catalyst if the call gains traction.The Company will host an investor conference call on Monday, October 13, 2025 at 8:30am ET to discuss the data collected to date from the ongoing Fully Resected Metastatic Osteosarcoma Trial and the regulatory path to conditional marketing authorization(s) for OST-HER2 in the United Kingdom, the United States and the European Union.
Well folks I hope you have a wonderful weekend. I am done for the day! In case someone wants to do a bitt research over the weekend I recommend Os therapies, they published positive news today but they didnβt had much volume today. The company will participate in the Cancer Spotlight Panel at BioFuture 2025 on October 13, 2025 to present on OST-HER2 and its development plans. In addition , Analysts have maintained or reiterated βBuyβ ratings on OSTX based on its clinical progress and regulatory strategy. OS Therapies (OSTX) will participate in the Daytime Emmy Awards in October 17, 2025. Just sending to those folks that want to do some research!
OSTX and RDZN let's pump!
OSTX news just popped, lets go!
OSTX, they have stage 2 FDA approval for their innovative cancer treatment for kids. The treatment is also good for the most common cancer in dogsβa huge market. Could see $18.00 in a year.
Can we get a good pump on OSTX please π₯Ί
OSTX has been vacillating between $2.05 and $2.20 for a couple weeks, sure hope it gets back to $2.20 AH because I keep buying dip and it seems to be biting me this time π’
OSTX on discount now for upcoming October Catalysts
Good time to grab some share of OSTX before potential October Catalysts, in a bit of a dip
lol, I hear you on aTyr; they spiked on Phase 2 data but didnβt pan out long-term. The point with OSTX is short-term potential: strong 2-year Phase 2b results, RMAT/Breakthrough designations, and a $100M+ PRV. Itβs not guaranteed, but if the October data impresses (which seems to be very likely), the stock could react big.
Whatβs happening with OSTX and, more importantly, when?
Go buy some $OSTX and thank me later π a real catalyst before a chatter
I'm interested to here what people think of OSTX
$OSTX on watch Tuesday, possibly good FDA news
Tuesday, big announcement for OS Theraputics! OSTX
OSTX -- not sure why there isn't any traction at all and FBIO for late Sep catalyst
Stocks that aren't IXHL or TNFA: IAUX XFOR OSTX AZTR UP Good luck out there.
I wouldn't sleep on OSTX. Big week coming up. The highest price target for OSTX is $20.00, while the lowest price target for OSTX is $15.00. Currently trading @ $2.40, up 40% this week. Upcoming 2025 Milestones: End of Phase 2 Meeting with FDA scheduled for August 27, 2025 regarding the OST-HER2 osteosarcoma program that is anticipated to provide the Company with the necessary insight to allow it to begin a rolling BLA submission Projected initiation of BLA submission in late Q3 2025 for OST-HER2, targeting the prevention of recurrent, fully resected, lung metastatic pediatric osteosarcoma following End of Phase 2 Meeting with FDA Rapporteur meeting with EMA scheduled for October 2025 Potential regulatory approval for OST-HER2 in the prevention or delay or recurrent, pulmonary metastatic osteosarcoma in the U.S. and U.K. as early as year-end 2025
XFOR isn't done yet. It's nearly done with printing its bull flag; next stop is the daily 200. That comes out to be 163% from where it is right now. That starts any day now. IAUX is the same story, but it's back through the 200 as of today, bullish engulfing the last 3 trading days. CTM? Scalp-worthy, but you're trading up on what's about to be a down trend. That's what I'm doing. OSTX popped through the daily 200 today, albeit with some reluctance. Worth watching. BURU sucks. Hope to never see that ticker show up here again.
OSTX is on the rise, currently 2.40, expected to reach 6-10 bucks
Everyone on this sub only talks about the bags they holding. Nobody talks about AEMD, OSTX, ASBP, etc Which really went X10 in past few weeks.
Here it comes . . . OSTX . . . just now popped above $2. Up 7.45%. Last chance!
OSTX is ready to pop I think.
What do you people think about OSTX, costs $1.85, price target is $20 lol
Potential poppers: QNCX, OSTX, GNPX. All three are trading under $2, and moved up at least 5% today. https://preview.redd.it/keovozv2rnif1.png?width=1842&format=png&auto=webp&s=34b949a5260c3d924083901fa3eeee1c96cdbb83
$OSTX The FDA has granted OS Therapies an End of Phase 2 meeting on August 27, 2025, to discuss their lead candidate, OST-HER2, for recurrent, pulmonary-metastatic osteosarcoma.Β This meeting is a significant catalyst as it will determine the path forward for a potential Biologics License Application (BLA) under Accelerated Approval.Β
OSTX good news for next month. https://www.stocktitan.net/news/OSTX/os-therapies-provides-clinical-global-regulatory-5z6hbkgtmf2v.html
Itβs wild how a ticker like $OSTX can get flooded with upvotes off a press release no oneβs actually talking about. Patent news is cool, sureβbut how many biotech plays have patents and still go nowhere? Letβs not act like this guarantees clinical success or revenue. Meanwhile, $AITX is cutting over $1.2M in waste, tightening ops, and inching toward positive cash flowβreal moves, not just paper IP hype.
Can someone explain the situation of OSTX?
I really don't understand.. Why is OSTX falling? Is it because of short selling?
OSTX volume doesn't stick...
OSTX [OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040](https://finance.yahoo.com/news/os-therapies-announces-issuance-u-124500681.html)
Hoping OSTX opens at $10
OSTX - halted, pending news. Watch it
Im also gonna once again tell yall to pay attention to OSTX. It's all there. You're a few weeks late, but the potential remains. Do your own research, but there are several posts on the penny stock page and in the lounge about it.
Where's OSTX man? Thanks for the call
Once again shouting out OSTX. The fundamentals and positive upcoming catalysts are all there. And if you don't care about any of that, just look at the chart. It's been climbing non stop and the volume is finally starting to increase
Took a shot in the dark, put my money in OSTX
Everyone's foaming at the mouth over these pump and dump gambles but let me put you onto OSTX, a company with solid fundamentals, no danger of delisting/reverse splitting/bankruptcy, huge upside potential according to analysts, and a number of positive upcoming catalysts. Not to mention it's been climbing steadily over the last 2 weeks with larger jumps over the last couple days as people are starting to take notice. The only thing this stock lacks is volume and that won't be for long.
I've been calling out OSTX for months. It's been nothing but positive news for this company but there just isn't much trade volume yet. It's way undervalued for what it is and just like at the end of the year, I'm expecting a short term pop to at least $4 in the next couple months, and long term higher than that
Appreciate the TA breakdown but from a biotech perspective, Iβd be cautious interpreting OSTXβs compression as a signal of fundamental strength. OS Therapies is still extremely early-stageβ¦ and the Advaxtis acquisition is mostly narrative at this point. thereβs no clinically de-risked asset in play yet.The FDA meeting they βsecuredβ isnβt a milestone itβs standard protocol, and no trial is currently enrolling. Pipeline visibility is limited, and thereβs zero indication of platform scalability or strategic differentiation in their data. So even with a tight float, the underlying story lacks the biological credibility that would justify sustained re-pricing.seen this setup before,retail volume pushes it through $1.70, then insiders or early holders fade into the rally. The burden of proof is on the pipeline now, not the tape.
Youβve moved on from $ACTU? This is only your 6th $OSTX post now.
OSTX: from obscurity to 'encouraging signs' overnight. Acquisition? Check. FDA meeting? Check. Now, will it moon or crater? Place your bets, folks. #BiotechRoulette
80% OSTX and 20% NAK OS Therapeutics imo is severely undervalued atm and going under the radar. They've got very positive study results and pending FDA approval.
OSTX OS Therapies (NYSE-A: OSTX) has secured a presentation slot at the MIB Agents Factor Osteosarcoma Conference in Salt Lake City (June 26-28, 2025) to showcase data from their Phase 2b clinical trial of OST-HER2. The trial focuses on preventing recurrent, fully resected, lung metastatic osteosarcoma. The company will present comparative data with a regulatorily compliant synthetic control group, which will be used for their upcoming FDA Biologics License Application (BLA). The company plans to submit the BLA in Q2 2025, with potential approval expected in Q4 2025. OST-HER2 has received multiple regulatory designations including: Rare & Pediatric Disease Designation from FDA Fast Track and Orphan Drug Designations from both FDA and EMA If approved before September 30, 2026, the company will receive a Priority Review Voucher (PRV), which can be sold to third parties. For reference, the most recent PRV was sold by Zevra for $150 million.
OSTX is toast bro I got screwed on that play
I put the rest of what Iβm willing to deposit in OSTX today. Good luck this week fellas
OSTX seems to be a good long term play
OSTX is the new play. Long term potential
Check out OSTX. Company just secured patent into 2040 in a billion dollar cancer drug sob-market and moved up in Premarket[https://www.stocktitan.net/news/OSTX/os-therapies-receives-patent-notice-of-allowance-from-u-s-patent-0gr92vc4anzz.html](https://www.stocktitan.net/news/OSTX/os-therapies-receives-patent-notice-of-allowance-from-u-s-patent-0gr92vc4anzz.html)
OSTX because of good news
Interesting picks! OSTX has some solid potential with that BLA submission. MBRX's big jump caught attention, could be a good one to track.
I traded OSTX Friday. Got in and out around 2.46 at break even. I was hoping for it to climb but it never could break 2.64, gave a few chances but got out even. Glad I got out before the weekend since it went down to 2.07 after market.
OSTX going parabolic right now
OSTX is my next pal to invest in
Hey lads, just wanted to draw attention to a company I've been interested in. It's OSTX - a biotech company that's been focusing on developing advanced therapies for osteosarcoma. While it's a smaller market, progress has been insane due to much research done on osteosarcoma through dogs. The company also generated statistically significant results in its clinical trial 2b of OST-HER2 for lung metastatic osteosarcoma. Recently, they've strategically acquired programs from another company, with clever financing. Here's the recent news: [https://www.stocktitan.net/news/OSTX/os-therapies-agrees-to-acquire-all-listeria-monotygenes-based-immuno-tzmyae911h6y.html](https://www.stocktitan.net/news/OSTX/os-therapies-agrees-to-acquire-all-listeria-monotygenes-based-immuno-tzmyae911h6y.html) . I purchased shares today at $1.95. It's been in a downtrend, further done by a dilution required to immediately pay for the acquisition. However, I see a reversal coming and so do several analysts who are quite optimistic about this company. Feel free to critique or discuss this matter with me and/or each other.
Okay can anyone take a look at OSTX and tell mΔ what the fuck is going on with that stock on 0 news mind you
Bought more CKPT today Its up 5%, issue is the stock I sold to buy it OSTX Is up 80 FUCKING PERCENT ON NO NEWS, FUCK ME 
What is the story on OSTX? They have been increasing significantly in recent days, and I still canβt really find any news on it.
Consider stocks near consolidation or recent dips; look for undervalued setups like SGMT or OSTX.
OSTX volatile; watch $3.00 support and $3.50 resistance closely.
Woo Woo Iβm in OSTX at $2.13 since 12/04 and am up 51.18%!!!
Up 90% on OSTX hold or sell? 
Should have went with OSTX :D nearly 100% up since 12.2.
I heard about OSTX on here months ago but no ones's really been talking about it since. Great company working on treatment for various types of cancer treatments with a couple studies approaching late phase results. Low float, and mooned this week without any public news. I got in around 3$, hodling till atleast 7$
Your post with title "Anybody saw the movement from last couple of days for OSTX? any news might coming? " has been automatically removed from r/PennyStocks for being low-effort/spam. (Low word count) probably by u/automod *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/pennystocks) if you have any questions or concerns.*
OSTX's pipeline looks strong. Their [OST-HER2 immunotherapy just finished Phase 2b trials with 41 patients](https://finance.yahoo.com/news/os-therapies-reports-third-quarter-144700839.html) and results coming in December. Not just another biotech - they already have conditional USDA approval for canine osteosarcoma treatment. Big potential revenue streams lined up. Out-licensing deals for canine OS ($15M+), human OS ($100M+), and their tADC platform ($20-80M). Plus a [priority review voucher worth $100-110M](https://finance.yahoo.com/news/join-os-therapies-exclusive-live-125100836.html) once they get FDA approval. They just [added two pharma veterans to the board](https://finance.yahoo.com/news/os-therapies-appoints-two-bio-204400770.html) - McKean Dieser from UCB and Jarry who worked at Bristol-Myers Squibb. Shows they're serious about commercialization. The chart looks ready to break out. Volume's picking up too. December data readout will be huge.
OSTX pumping today https://preview.redd.it/y5mqgjpre26e1.png?width=702&format=png&auto=webp&s=0fec25b980991e1e929e0c3fc77ce26f335552de 
Did Martin Shkreli analyze OSTX?
Haven't checked on OSTX in a minute. Been waiting for those trial results with the OST-HER2